The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dose-Dense Chemotherapy for Breast Cancer

Clifford A. Hudis, MD
Published Online: 7:19 PM, Wed March 4, 2015
Clifford A. Hudis, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses dose-dense chemotherapy for the treatment of patients with breast cancer.

Clinical Pearls

  • Early mathematical models suggested scheduling might be a viable alternative strategy to escalating the dose of conventional cytotoxic chemotherapies.
  • The big breakthrough in this area was the development of growth factors in the 1980s and 1990s.
  • This strategy represents a useful backbone for targeted therapies.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.